Create Free Account

By creating account you will get access to hot stocks & personalised emails

Biotron Ltd

Healthcare AU BIT

0.018AUD
-(-%)

Last update at 2024-12-30T04:39:00Z

Day Range

0.020.02
LowHigh

52 Week Range

0.020.12
LowHigh

Fundamentals

  • Previous Close 0.02
  • Market Cap15.34M
  • Volume116111
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.50449M
  • Revenue TTM1.65M
  • Revenue Per Share TTM0.002
  • Gross Profit TTM 1.43M
  • Diluted EPS TTM-

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -3.49277M -2.78108M -3.19435M -3.57596M -1.61180M
Minority interest - - - - -
Net income -3.49277M -2.78613M -4.65755M -3.57596M -0.44983M
Selling general administrative 0.70M 1.12M 1.13M 1.12M 1.17M
Selling and marketing expenses 0.93M - - - -
Gross profit 1.43M -1.26261M -1.67468M 0.05M 0.05M
Reconciled depreciation 0.04M 0.05M 0.05M 0.05M 0.01M
Ebit -3.60804M -2.77603M -3.19309M -3.57084M -2.77377M
Ebitda -3.60155M -2.73078M -3.14575M -3.52072M -2.76130M
Depreciation and amortization 0.00649M 0.05M 0.05M 0.05M 0.01M
Non operating income net other - - - - -
Operating income -3.60804M -2.77603M -3.19309M -3.64017M -2.77377M
Other operating expenses 5.04M 4.34M 4.67M 4.44M 2.77M
Interest expense 0.00439M 0.00505M 0.00126M 0.00512M 0.00512M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.12M 0.00309M 0.01M 0.06M 0.09M
Net interest income 0.12M -0.00196M 0.01M -0.00512M 0.09M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.44M 0.00505M 1.46M 0.76M -1.16197M
Total revenue 1.43M 1.56M 1.46M 0.05M 0.05M
Total operating expenses 5.04M 4.34M 4.67M 4.44M 2.77M
Cost of revenue 3.23M 2.82M 3.14M 2.86M 1.12M
Total other income expense net 0.12M -0.00505M -0.00126M 0.75M 1.16M
Discontinued operations - - - - -
Net income from continuing ops -3.49277M -2.78108M -3.19435M -3.57596M -1.61180M
Net income applicable to common shares -3.49277M -2.78108M -3.19435M -3.57596M -1.61180M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 0.49M 4.14M 1.91M 4.33M 7.83M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.02M 0.02M 0.02M 0.05M 0.06M
Total liab 0.74M 0.96M 0.81M 0.46M 0.85M
Total stockholder equity -0.24403M 3.17M 1.09M 3.86M 6.97M
Deferred long term liab - - - - -
Other current liab 0.44M 0.67M 0.44M 0.31M 0.53M
Common stock 56.91M 56.89M 52.84M 52.84M 52.84M
Capital stock - 56.89M 52.84M 52.84M 52.84M
Retained earnings -58.68079M -55.26377M -51.83737M -49.08691M -45.94507M
Other liab - - 0.02M 0.01M 0.00913M
Good will - - - - -
Other assets - 0.05M 0.05M 0.03M 0.03M
Cash 0.39M 3.98M 1.74M 4.21M 7.66M
Cash and equivalents - - - - -
Total current liabilities 0.74M 0.96M 0.75M 0.45M 0.84M
Current deferred revenue - -0.03858M -0.11248M -0.00635M -0.04071M
Net debt -0.38607M -3.93912M -1.66417M -4.20428M -7.61688M
Short term debt 0.00713M 0.04M 0.03M 0.00635M 0.04M
Short long term debt - - - - -
Short long term debt total 0.00713M 0.05M 0.08M 0.00635M 0.04M
Other stockholder equity - -1.62663M -1.00662M -3.75708M -6.89893M
Property plant equipment - 0.05M 0.09M 0.03M 0.07M
Total current assets 0.43M 4.03M 1.76M 4.26M 7.72M
Long term investments - - - - 0.03M
Net tangible assets - 3.17M 1.09M 3.86M 6.97M
Short term investments - - - - -
Net receivables 0.02M 0.02M - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.29M 0.29M 0.39M 0.14M 0.31M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.52M 1.55M 0.09M 0.11M 0.07M
Additional paid in capital - - - - -
Common stock total equity - - - - 52.84M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.05M 0.05M 0.03M 0.03M
Deferred long term asset charges - - - - -
Non current assets total 0.07M 0.10M 0.14M 0.06M 0.11M
Capital lease obligations - 0.05M 0.08M 0.00635M 0.04M
Long term debt total - 0.00669M 0.04M 0.00000M 0.00331M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments - - -0.00572M - -0.05288M
Change to liabilities 0.15M 0.20M -0.36541M 0.12M 0.06M
Total cashflows from investing activities 0.00000M 0.00000M -0.00572M -0.00572M -0.05288M
Net borrowings -0.03991M -0.03317M -0.03696M -0.03298M -0.03298M
Total cash from financing activities 5.53M -0.03317M -0.03696M 5.00M 5.75M
Change to operating activities -0.02595M 0.01M 0.00718M 0.23M -0.00056M
Net income -3.49277M -2.78108M -3.19435M -3.57596M -0.44983M
Change in cash 2.24M -2.46922M -3.45028M 1.92M 4.20M
Begin period cash flow 1.74M 4.21M 7.66M 5.74M 1.54M
End period cash flow 3.98M 1.74M 4.21M 7.66M 5.74M
Total cash from operating activities -3.29004M -2.43605M -3.40760M -3.08182M -1.49789M
Issuance of capital stock 6.00M - - 5.31M 6.04M
Depreciation 0.04M 0.05M 0.05M 0.05M 0.01M
Other cashflows from investing activities - - - 0.00000M -0.01195M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock -0.42780M -0.42780M 0.00000M -0.27543M -0.29168M
Other cashflows from financing activities -0.03991M -0.03317M -0.03696M -0.03298M -0.05288M
Change to netincome 0.04M 0.09M 0.10M 0.09M 0.04M
Capital expenditures 0.00000M 0.00000M 0.00572M 0.00572M 0.04M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -2.95028M -2.61665M -3.48772M -2.44233M -0.99082M
Stock based compensation - 0.01M 0.08M 0.07M -
Other non cash items 0.16M 0.29M -0.34492M 0.37M 1.60M
Free cash flow -3.29004M -2.43605M -3.41332M -3.08182M -1.53882M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BIT
Biotron Ltd		 - -% 0.02 - - 9.32 8.21 358.89 -11.3179
CSL
CSL Ltd		 0.72 0.26% 283.07 32.16 27.40 9.19 4.89 6.50 20.17
TLX
Telix Pharmaceuticals Ltd		 -0.28 1.12% 24.67 166.27 77.52 12.93 20.73 12.99 113.45
MSB
Mesoblast Ltd		 0.07 2.47% 2.90 - 454.55 496.55 3.81 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.14 1.13% 12.20 12.08 35.21 8.21 4.53 5.53 7.21

Reports Covered

Stock Research & News

View All

Profile

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is based in Sydney, Australia.

Biotron Ltd

56 Delhi Road, Sydney, NSW, Australia, 2113

Key Executives

Name Title Year Born
Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. MD & Exec. Director NA
Mr. Peter James Nightingale B.Econ, CA Company Sec. 1957
Dr. Stephen L. Becker M.D. Chief Medical Officer NA
Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. MD & Executive Director NA
Mr. Peter James Nightingale B.Econ, CA Company Secretary 1957
Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. MD & Executive Director NA
Mr. Peter James Nightingale B.Econ, CA Company Secretary 1957
Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. MD & Executive Director NA
Mr. Peter James Nightingale B.Econ, CA Company Secretary 1957
Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. MD & Executive Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.